NuVasive (NUVA) Updates FY12 Earnings Guidance
NuVasive (NUVA) updated its FY12 earnings guidance on Wednesday. The company provided earnings per share guidance of $0.88-0.90 for the period.
A number of research firms have also recently commented on NUVA. Analysts at Barclays Capital downgraded shares of NuVasive from an overweight rating to an equalweight rating in a research note to investors on Thursday, October 4th. On a related note, analysts at Canaccord Genuity reiterated a buy rating on shares of NuVasive in a research note to investors on Thursday, October 4th. They now have a $21.00 price target on the stock. Finally, analysts at First Analysis reiterated an equal weight rating on shares of NuVasive in a research note to investors on Thursday, October 4th.
NuVasive (NUVA) traded up 10.75% on Wednesday, hitting $14.01. NuVasive (NUVA) has a 52-week low of $11.02 and a 52-week high of $25.99. The company’s market cap is $609.0 million.
NuVasive last posted its quarterly earnings results on Wednesday, October 24th. The company reported $0.23 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.21 by $0.02. NuVasive’s revenue was up 11.7% compared to the same quarter last year. Analysts expect that NuVasive (NUVA) will post $0.94 EPS for the current fiscal year.
NuVasive, Inc. (NuVasive) is a medical device company. NuVasive focuses on developing minimally disruptive surgical products and procedures for the spine.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.